Superblood: The Development of Novel Red-Cell Therapeutics

In an Interview with Sonia Portillo and Peter Hofland, the team behind The Onco'Zine Brief, David R. Epstein BSc, MBA, the Executive Chairman of Rubius Therapeutics, explains how his company is pioneering novel Red-Cell Therapeutics or RCTs – nicknamed ‘superblood’ – as a new class of medicines to address a wide array of diseases. Epstein explains how these novel drugs have leading applications in cancer, rare and autoimmune disease, as well as additional potential in hemophilia, infectious and metabolic diseases.